Hexachlorophene

Hexachlorophene was developed in the 1940s by Givaudan Corporation, and its exceptional bactericidal activity against gram-positive bacteria (particularly Staphylococcus) made it the antiseptic of choice for hospital nurseries and surgical scrubs through the 1950s and 1960s. [1] Commercial products like pHisoHex (hexachlorophene + emollient) were widely used in hospitals — newborns were routinely bathed in dilute hexachlorophene solutions to prevent Staphylococcal nursery epidemics. It was also a common ingredient in consumer antibacterial soaps, deodorants, and cosmetics. The toxicity story unfolded on multiple fronts. In 1972, a pharmaceutical error in France contaminated talcum powder with hexachlorophene (at 6% concentration instead of 0.1%), resulting in the deaths of 36 infants and neurological damage in many more. [2] Simultaneously, US studies revealed that even routine nursery bathing in dilute hexachlorophene (3% solutions) was causing subcortical white matter damage (spongiform myelinopathy) in premature infants, who absorb the compound far more efficiently through their immature skin than term infants. The FDA restricted hexachlorophene to prescription-only status in 1972 and banned it from over-the-counter consumer products, including the consumer version of pHisoHex. [3] Today it remains available as a prescription surgical scrub (Phisohex) and is used in controlled settings for specific surgical skin preparation, but the routine infant bathing use has completely ceased.

Current consumer exposure is negligible since the FDA ban. Healthcare workers using prescription hexachlorophene surgical scrubs absorb some through intact skin during routine use. Some agricultural uses (soil fungicide) provide occupational exposure for farm workers. Historical consumer exposures were widespread — the compound accumulated in human breast milk and was measurable in human body fat among individuals who used hexachlorophene-containing products regularly.

The mechanism of neurotoxicity is spongiform myelinopathy — hexachlorophene selectively damages the myelin sheath of axons in the brain and spinal cord, creating microscopic fluid-filled vacuoles (spongy degeneration) that impair nerve conduction. [2] Premature and newborn infants are uniquely susceptible because their immature skin has much higher percutaneous absorption rates and their developing brains are particularly vulnerable to myelinopathy. In adults, chronic occupational exposures have caused peripheral neuropathy, weakness, and in severe cases, cerebral edema and death. The historical infant deaths and neurological outcomes represent one of the most significant iatrogenic chemical disasters in pediatric medicine.

Current risk is limited to healthcare workers using prescription hexachlorophene surgical scrubs, who absorb low amounts through intact skin with repeated use. Historical risk affected nursery nurses and parents who used hexachlorophene products on infants. No current consumer exposure from personal care products.

1. Do not use hexachlorophene-containing products on infants — these are prescription products and appropriate only under medical supervision for specific surgical prep. 2. Healthcare workers using hexachlorophene surgical scrubs should minimize contact time and follow product instructions. 3. The FDA restriction means no over-the-counter hexachlorophene products should be available; report any unlabeled or non-compliant products to the FDA.